Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+Reports+Dosing+in+Novartis+%28NVS%29+Phase+12+Using+Bilateral+Hearing+Loss+Treatment+Tech/9951089.html for the full story.
GenVec, Inc. (GNVC)
Q4 2013 Earnings Conference Call
March 28, 2014 10:00 a.m. ET
Douglas Swirsky - President and CEO
Douglas Brough - Chief Scientific Officer
James Lambert - Senior Director of Accounting & Finance
NEW YORK (TheStreet) -- Shares of GenVec Inc. were up 12.83% to $2.99 in aftermarket trading Thursday. The jump comes ahead of the company posting its fiscal 2013 fourth quarter earnings on Friday.Consensus EPS forecast for the company is - 10...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.